EU Approves VaxRabeo Rabies Vaccine for All Ages
The European Commission authorized the Sanofi-developed vaccine for pre- and post-exposure prophylaxis after a positive EMA opinion.
Updated on Nov. 19, 2026 in Diseases — General

Live Poll
Would you get a rabies vaccine if you were bitten by a stray animal?
The European Commission approved VaxRabeo for rabies prophylaxis in all age groups, its first marketing authorisation, following a positive opinion from the European Medicines Agency's CHMP on September 17, 2026. The vaccine is approved for both pre-exposure and post-exposure use.
Why it matters
Rabies causes an estimated 59,000 deaths worldwide each year, and the approval adds a new Vero-cell vaccine option for prevention across all age groups. Clinical comparisons with Verorab and Imovax Rabies showed comparable protective antibody levels in pre-exposure use and a similar immunogenicity profile after exposure.
The approval rests on a clinical programme comparing VaxRabeo with Verorab and Imovax Rabies, which showed comparable protective antibody levels in pre-exposure prophylaxis and a similar immunogenicity profile in post-exposure settings. The source does not provide sample sizes or antibody titre values.
The players
Sanofi
A French multinational pharmaceutical company headquartered in Paris, active in vaccines and prescription medicines worldwide.
European Medicines Agency
The EU agency responsible for the scientific evaluation and supervision of medicines, whose CHMP issues the positive opinions that precede European marketing authorisation.
The details
VaxRabeo is manufactured using Vero-cell technology and formulated to minimize the risk of allergic reactions, with a 60-month shelf life. The vaccine is approved for pre-exposure and post-exposure prophylaxis for all age groups.
Timeline
September 17, 2026: EMA's CHMP adopted a positive opinion on VaxRabeo.
November 19, 2026: The European Commission approved VaxRabeo for all age groups.
Big Picture
VaxRabeo joins Verorab and Imovax Rabies as a Vero-cell rabies vaccine, adding a newly authorised option benchmarked directly against both incumbents. The approval widens the set of prophylaxis choices available across the EU for an infection that remains a major cause of death in Asia and Africa.
For travelers and people exposed to animals in endemic regions, VaxRabeo offers an additional pre-exposure and post-exposure option across all age groups. Children under 15 account for 40% of people bitten by suspect rabid animals, making age-inclusive approval relevant to family health planning.
The takeaway
Rabies is preventable with timely vaccination, and the approval of VaxRabeo adds another Vero-cell option for pre- and post-exposure use. Anyone bitten or scratched by a potentially rabid animal should seek medical advice promptly.
Further reading
For more on rabies and other infectious threats, see Diseases — General.
Source note: This article includes information reported by The Manila times.
Live Poll
Would you get a rabies vaccine if you were bitten by a stray animal?



